Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Salix: FDA Approves Fulyzaq 125 Mg Tablets For Diarrhea In HIV/AIDS Patients

RELATED NEWS
Trade SLXP now with 

Salix Pharmaceuticals, Ltd. (SLXP: Quote) Wednesday said the Food and Drug Administration approved Fulyzaq, or crofelemer, 125 mg delayed-release tablets for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS, who are on anti-retroviral therapy or ART.

Fulyzaq is a locally-acting, minimally-absorbed drug derived from a botanical source. It is not available synthetically and Salix has the right to the manufacturing process for producing Fulyzaq from the biologic source.

Patents for Fulyzaq is expected to provide intellectual property protection to 2018. Fulyzaq is eligible for market exclusivity for five years as a new molecular entity in the U.S. and the product may be entitled to patent term restoration. The drug is expected to become accessible to patients in early 2013.

The drug is believed to act by blocking chloride secretion and thus reducing the accompanying high volume water loss as seen in HIV-associated diarrhea.

It is this secretion that is said to lead to diarrhea with the associated symptoms of dehydration, electrolyte imbalance, abdominal cramping, urgency and increased frequency.

The FDA approval of Fulyzaq is based on a randomized, double-blind, placebo-controlled and placebo-free, multi-center study of 374 HIV-positive patients on ART, with a history of diarrhea for one month or more.

The primary efficacy endpoint was the proportion of patients experiencing less than or equal to two watery bowel movements per week, during at least two of the four weeks of the placebo-controlled phase.

Data showed that a significantly larger proportion of patients taking Fulyzaq 125 mg twice daily experienced clinical response compared to patients in the placebo group. Significant reductions from baseline to the end of the double-blind period also were observed for the number of watery bowel movements per day, and daily stool consistency score.

The Phase 3 study showed that Fulyzaq did not influence the efficacy or safety of the patients' HIV medications. The most common adverse reactions were respiratory tract infection, bronchitis, cough, flatulence and increased bilirubin.

SLXP closed at $40.47 on Monday.

Register
To receive FREE breaking news email alerts for Salix Pharmaceuticals Ltd and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
First-time claims for U.S. unemployment benefits fell by much more than anticipated in the week ended September 13th, according to a report released by the Labor Department on Thursday, with claims pulling back near the fourteen-year low set in July. After ending the previous session mostly higher, stocks may see some further upside in early trading on Thursday. The major index futures are currently pointing to a higher open for the markets, with the Dow futures up by 44 points. Banks took up less-than-expected amount of funds at the European Central Bank's first targeted longer term refinancing operation, damping hopes of the success of the measure that was aimed to boost liquidity to help revive lending to small businesses and households.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.